EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Similar Trend in Benefit of Adjuvant Platinum in Lung Cancer Patients Irrespective of Epidermal Growth Factor Receptor Mutation Status

Kenichi Suda iD, Kosuke Fujino, Mao Yoshikawa, Kazuhiko Shien, Ken Suzawa iD, Kotaro Nomura, Shota Fukuda, Shuta Ohara, Akira Hamada, Fumihiko Kinoshita, Kazuki Hayasaka, Hirotsugu Notsuda und 7 weitere

European Journal of Cardio-Thoracic Surgery · 2025

DOI: 10.1093/ejcts/ezaf239 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Cardio-Thoracic Surgery, 2025. Verfasst von Kenichi Suda und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama 589-8511, Japan. Hauptthemen laut MEDLINE: Lung Neoplasms, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Adjuvant osimertinib is currently the standard of care after pulmonary resection in patients with non-small cell lung cancer (NSCLC) harbouring an activating epidermal growth factor receptor (EGFR) mutation. Several guidelines recommended up to 4 cycles of adjuvant platinum-doublet before adjuvant osimertinib treatment. However, whether adjuvant platinum-doublet prolongs the overall survival (OS) of patients with EGFR-mutated NSCLC as it did in the unselected LACE meta-analysis cohort is unclear.

Methods

A multicentre retrospective observational study was conducted at 21 centres in Japan, enrolling 4181 patients with lung adenocarcinoma who received pulmonary resection between 2015 through 2018. In this study, we compared the efficacy of adjuvant platinum-doublet between EGFR mutated and EGFR wild-type cohort focusing on 706 patients with pathological stage II-III disease. Propensity score matching (1:1 ratio, caliper = 0.2) was used to balance patient characteristics (age, sex, smoking, preoperative performance status, pathological stage, and EGFR status) between patients who received adjuvant treatment and those who did not.

Results

Among the 706 patients, 391 (55%) received adjuvant platinum-doublet. After 1:1 propensity score matching, patient characteristics were well balanced in the 2 groups (201 patients each). In subgroup analysis of overall and recurrence-free survival, the hazard ratios of adjuvant treatment were similar in the EGFR-mutated and EGFR wild-type groups (eg, OS, 0.56 [95% CI, 0.29-1.10] and 0.52 [95% CI, 0.33-0.82] in EGFR-mutated and EGFR wild-type subgroup, respectively).

Conclusions

Adjuvant platinum-doublet chemotherapy showed similar trends of benefit in the EGFR-mutated and EGFR wild-type subgroups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsMutationAgedFemaleHumansMaleMiddle AgedCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantErbB ReceptorsJapanPneumonectomyRetrospective StudiesAcrylamidesAniline CompoundsIndolesPyrimidines

Stichwörter der Autor:innen

adjuvant treatmentepidermal growth factor receptor (EGFR) mutationoverall survivalpropensity score matching

Substanzen

EGFR protein, humanErbB ReceptorsosimertinibAcrylamidesAniline CompoundsIndolesPyrimidines

Autor:innen und Institutionen

  • Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama 589-8511, Japan.
  • Department of Thoracic Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860-8556, Japan.
  • Department of Thoracic Surgery, Okayama University Hospital, Okayama 700-8558, Japan.
  • Department of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa 277-8577, Japan.
  • Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan.
  • Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.

ORCID-Profile: Kenichi Suda, Ken Suzawa, Shinkichi Takamori, Junichi Soh

Zitieren

APA

Suda, K., Fujino, K., Yoshikawa, M., Shien, K., Suzawa, K., Nomura, K., Fukuda, S., Ohara, S., Hamada, A., Kinoshita, F., Hayasaka, K., Notsuda, H., Takamori, S., Muto, S., Katsumata, S., Shimokawa, M., Soh, J., Tsutani, Y., & CReGYT-EGFR Study Group (2025). Similar Trend in Benefit of Adjuvant Platinum in Lung Cancer Patients Irrespective of Epidermal Growth Factor Receptor Mutation Status. European Journal of Cardio-Thoracic Surgery. https://doi.org/10.1093/ejcts/ezaf239

Vancouver

Suda K, Fujino K, Yoshikawa M, Shien K, Suzawa K, Nomura K, et al. Similar Trend in Benefit of Adjuvant Platinum in Lung Cancer Patients Irrespective of Epidermal Growth Factor Receptor Mutation Status. European Journal of Cardio-Thoracic Surgery. 2025. doi:10.1093/ejcts/ezaf239

BibTeX
@article{Suda2025,
  author = {Suda, Kenichi and Fujino, Kosuke and Yoshikawa, Mao and Shien, Kazuhiko and Suzawa, Ken and Nomura, Kotaro and Fukuda, Shota and Ohara, Shuta and Hamada, Akira and Kinoshita, Fumihiko and Hayasaka, Kazuki and Notsuda, Hirotsugu and Takamori, Shinkichi and Muto, Satoshi and Katsumata, Shinya and Shimokawa, Mototsugu and Soh, Junichi and Tsutani, Yasuhiro and CReGYT-EGFR Study Group, CReGYT-EGFR Study Group},
  title = {Similar Trend in Benefit of Adjuvant Platinum in Lung Cancer Patients Irrespective of Epidermal Growth Factor Receptor Mutation Status},
  journal = {European Journal of Cardio-Thoracic Surgery},
  year = {2025},
  doi = {10.1093/ejcts/ezaf239}
}
Kostenlos starten →